Bruton’s tyrosine kinase inhibitors [39,40,41], such as ibrutinib [42,43,44], have demonstrated remarkable CNS penetration and efficacy in primary and secondary CNS lymphomas, particularly in tumors harboring MYD88 mutations. The gene discussed is MYD88; the disease is primary central nervous system lymphoma.